These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 12455727)

  • 41. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients.
    Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC
    J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556
    [No Abstract]   [Full Text] [Related]  

  • 42. Economic evaluation of sirolimus-based immunosuppressive regimens in kidney graft recipients.
    Niemczyk M; Nowak M; Pilecki T; Wyzgał J; Ziółkowski J; Zygier D; Paczek L
    Transplant Proc; 2006; 38(1):74-7. PubMed ID: 16504668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.
    Trompeter R; Filler G; Webb NJ; Watson AR; Milford DV; Tyden G; Grenda R; Janda J; Hughes D; Ehrich JH; Klare B; Zacchello G; Bjorn Brekke I; McGraw M; Perner F; Ghio L; Balzar E; Friman S; Gusmano R; Stolpe J
    Pediatr Nephrol; 2002 Mar; 17(3):141-9. PubMed ID: 11956848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany.
    Jürgensen JS; Ikenberg R; Greiner RA; Hösel V
    Eur J Health Econ; 2015 May; 16(4):377-90. PubMed ID: 24728542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
    Filler G; Webb NJ; Milford DV; Watson AR; Gellermann J; Tyden G; Grenda R; Vondrak K; Hughes D; Offner G; Griebel M; Brekke IB; McGraw M; Balzar E; Friman S; Trompeter R
    Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients.
    Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP
    Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.
    Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS
    Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.
    Dantal J; Hourmant M; Cantarovich D; Giral M; Blancho G; Dreno B; Soulillou JP
    Lancet; 1998 Feb; 351(9103):623-8. PubMed ID: 9500317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-year observational results.
    Krämer BK; Montagnino G; Krüger B; Margreiter R; Olbricht CJ; Marcen R; Sester U; Kunzendorf U; Dietl KH; Rigotti P; Ronco C; Hörsch S; Banas B; Mühlbacher F; Arias M;
    Transpl Int; 2016 Mar; 29(3):307-14. PubMed ID: 26565071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of new immunosuppressive regimens on cost of renal transplant maintenance immunosuppression.
    Gentil MA; González-Roncero F; Cantarell C; López M; Marco J
    Transplant Proc; 2005 Apr; 37(3):1441-2. PubMed ID: 15866631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
    Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
    Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
    Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
    Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation.
    Snowsill TM; Moore J; Mujica Mota RE; Peters JL; Jones-Hughes TL; Huxley NJ; Coelho HF; Haasova M; Cooper C; Lowe JA; Varley-Campbell JL; Crathorne L; Allwood MJ; Anderson R
    Nephrol Dial Transplant; 2017 Jul; 32(7):1251-1259. PubMed ID: 28873970
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.
    Peters DH; Fitton A; Plosker GL; Faulds D
    Drugs; 1993 Oct; 46(4):746-94. PubMed ID: 7506654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.
    Plosker GL; Foster RH
    Drugs; 2000 Feb; 59(2):323-89. PubMed ID: 10730553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.